GENT Stock Overview
Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Launching NT-proBNP Test And Expanding Partnerships Will Broaden Cardiology Portfolio
My Notes
Capture your thoughts, links and company narrative
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 49.40 |
| 52 Week High | NOK 61.00 |
| 52 Week Low | NOK 34.80 |
| Beta | 0.56 |
| 1 Month Change | 22.28% |
| 3 Month Change | 19.90% |
| 1 Year Change | 21.38% |
| 3 Year Change | -14.53% |
| 5 Year Change | -17.39% |
| Change since IPO | 90.00% |
Recent News & Updates
Recent updates
Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce
Feb 07
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%
Jun 29Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14Shareholder Returns
| GENT | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | 1.6% | 3.3% | -0.3% |
| 1Y | 21.4% | 15.0% | 8.6% |
Return vs Industry: GENT exceeded the Norwegian Medical Equipment industry which returned 15% over the past year.
Return vs Market: GENT exceeded the Norwegian Market which returned 8.6% over the past year.
Price Volatility
| GENT volatility | |
|---|---|
| GENT Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 12.0% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: GENT has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: GENT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Njaal Kind | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| GENT fundamental statistics | |
|---|---|
| Market cap | NOK 761.86m |
| Earnings (TTM) | NOK 45.29m |
| Revenue (TTM) | NOK 152.07m |
16.8x
P/E Ratio5.0x
P/S RatioIs GENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENT income statement (TTM) | |
|---|---|
| Revenue | NOK 152.07m |
| Cost of Revenue | NOK 69.25m |
| Gross Profit | NOK 82.82m |
| Other Expenses | NOK 37.52m |
| Earnings | NOK 45.29m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Mar 21, 2025
| Earnings per share (EPS) | 2.94 |
| Gross Margin | 54.46% |
| Net Profit Margin | 29.78% |
| Debt/Equity Ratio | 0% |
How did GENT perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield14%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 03:30 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martinsson | DNB Markets |
| Geir Holom | DNB Markets |